As of November 6, 2026, BioCryst Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: BCRX); its largest reported holder is Deerfield Mgmt, L.P., with 6.81% on Schedule 13G/A of February 12, 2026, then RA Capital (6.2%). The largest insider holding is Jon P. Stonehouse, a director, with 1,420,419 shares (0.55% of shares outstanding), per Form 4 of September 2, 2026 (Schedule 13G/A, February 12, 2026).
Is this your company?
About to sign with, pay or invest in BioCryst Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is BioCryst Pharmaceuticals, Inc. a real, registered company?
- BioCryst Pharmaceuticals, Inc. files with the SEC under CIK 882796 (its SEC filings).
- Its shares are listed under the ticker BCRX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Durham, North Carolina, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under BioCryst Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Layoffs: 2 exit or restructuring plans reported on Form 8-K, Item 2.05 (latest filed 2026-08-04).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names RA Capital (filed 2026-08-14).
Who are BioCryst Pharmaceuticals, Inc.'s owners and officers?
BioCryst Pharmaceuticals, Inc.: incorporated in Delaware; business address in Durham, North Carolina; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Ra Capital Management, L.P. | 6.2% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 6% |
| Schedule 13G, 2026-05-12 | State Street Corporation | 4.9% |
| Schedule 13G, 2026-04-29 | Vanguard Capital Management | 5.16% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-12 | Deerfield Mgmt, L.P. | 6.81% |
| Schedule 13G, 2026-02-09 | State Street Corporation | 5.3% |
| Schedule 13G, 2025-11-12 | Ra Capital Management, L.P. | 7.3% |
| Schedule 13G, 2025-09-19 | Deerfield Mgmt, L.P. | 5.8% |
Questions about who owns BioCryst Pharmaceuticals, Inc.
Who owns BioCryst Pharmaceuticals, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of BioCryst Pharmaceuticals, Inc.: Deerfield Mgmt, L.P. (6.81%, Schedule 13G/A, filed 2026-02-12), Ra Capital Management, L.P. (6.2%, Schedule 13G/A, filed 2026-08-14), State Street Corporation (6%, Schedule 13G, filed 2026-08-07) and Vanguard Capital Management (5.16%, Schedule 13G, filed 2026-04-29).
Who are the largest shareholders of BioCryst Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of BioCryst Pharmaceuticals, Inc. on this page are Deerfield Mgmt, L.P. (6.81%), Ra Capital Management, L.P. (6.2%) and State Street Corporation (6%).
When did Deerfield Mgmt, L.P. buy into BioCryst Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Deerfield Mgmt, L.P. on this page is the Schedule 13G, filed 2025-09-19, reporting 5.8%; its latest, Schedule 13G/A filed 2026-02-12, reports 6.81%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on BioCryst Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on BioCryst Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioCryst Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own BioCryst Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 1,420,419 shares (0.55% of shares outstanding), 1,340,419 held directly and 80,000 indirectly (Form 4, 2026-09-02).
- , the president and chief commercial officer: 952,583 shares (0.37% of shares outstanding) (Form 4, 2025-12-23).
- , the chief legal officer: 400,703 shares (0.16% of shares outstanding) (Form 4, 2026-05-15).
- , the chief financial officer: 377,867 shares (0.15% of shares outstanding) (Form 4, 2024-12-23).
- , the chief r and d officer: 377,318 shares (0.15% of shares outstanding) (Form 4, 2025-04-02).
Shares outstanding: 257,299,269 as of 2026-10-30, from the company's latest SEC cover page.
How much has BioCryst Pharmaceuticals, Inc. raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-01-23).
Red flags found
2 exit or restructuring plans on Form 8-K (latest Form 8-K, 2026-08-04).
Keep reading
More on BioCryst Pharmaceuticals, Inc. and the records around it.
BioCryst Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Layoff notices Aug 2026
Companies that share a holder
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
- STATE STREET CORPORATION also filed stake reports on 343 other companies: TRADE DESK INC/THE (Oct 2026), CENTRUS ENERGY CORP (Sep 2026), ACADIA PHARMACEUTICALS INC (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/biocryst-pharmaceuticals